EGFR T790M/FAK-IN-2

EGFR T790M/FAK-IN-2 是一种具有口服活性的双重 FAK 和 EGFRT790M 激酶抑制剂,对 FAK 的 IC50 为 1.03 nM,对 EGFRT790M 的 IC50 为 3.89 nM,可在过表达 FAK 的耐药癌细胞中发挥抗增殖作用并诱导细胞凋亡 (apoptosis) 和细胞周期阻滞,在胰腺癌异种移植小鼠模型中具有抗肿瘤活性,可用于胰腺癌、乳腺癌、非小细胞肺癌的研究。
产品编号: MS-X47495 CAS No.: 2143104-11-2 分子式: C25H28ClN7O3 分子量: 510.00
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

EGFR T790M/FAK-IN-2 是一种具有口服活性的双重 FAK 和 EGFRT790M 激酶抑制剂,对 FAK 的 IC50 为 1.03 nM,对 EGFRT790M 的 IC50 为 3.89 nM,可在过表达 FAK 的耐药癌细胞中发挥抗增殖作用并诱导细胞凋亡 (apoptosis) 和细胞周期阻滞,在胰腺癌异种移植小鼠模型中具有抗肿瘤活性,可用于胰腺癌、乳腺癌、非小细胞肺癌的研究。

生物实验数据

生物活性 EGFR T790M/FAK-IN-2 is an orally active dual FAK and EGFRT790M kinase inhibitor with an IC50 of 1.03 nM for FAK and 3.89 nM for EGFRT790M, which exerts antiproliferative effects and induces apoptosis and cell cycle arrest in FAK-overexpressing drug-resistant cancer cells, exhibits antitumor activity in a pancreatic cancer xenograft mouse model, and can be used for research on pancreatic cancer, breast cancer, and non-small cell lung cancer.
体外研究
(In Vitro)

EGFR T790M/FAK-IN-2 (Compound 9a) (1.25-40 μM; 72 h) 可抑制 AsPC-1、BxPC-3、Panc-1、Hpde6-c7、MCF-7/adr 及 H1975 细胞的增殖,其 IC50 值范围为 0.333 μM 至 1.347 μM。
EGFR T790M/FAK-IN-2 (0.5-8 μM; 24-72 h) 可呈剂量和时间依赖性降低 AsPC-1 和 Panc-1 细胞的活力。
EGFR T790M/FAK-IN-2 (0-1 μM; 72 h) 可在体外以剂量依赖方式诱导 AsPC-1 细胞发生凋亡。
EGFR T790M/FAK-IN-2 (0.25-1.0 μM; 72 h) 可呈剂量依赖性将 AsPC-1 细胞阻滞于 G2/M 期。

Cell Proliferation Assay

Cell Line: AsPC-1, BxPC-3, Panc-1, Hpde6-c7, MCF-7/adr, H1975 human cancer cell lines
Concentration: 1.25-40 μM
Incubation Time: 72 h
Result: Inhibited proliferation of AsPC-1 cells with an IC50 of 0.909 μM.
Inhibited proliferation of BxPC-3 cells with an IC50 of 0.761 μM.
Inhibited proliferation of Panc-1 cells with an IC50 of 1.218 μM.
Inhibited proliferation of Hpde6-c7 cells with an IC50 of 1.347 μM.
Inhibited proliferation of MCF-7/adr cells with an IC50 of 0.892 μM.
Inhibited proliferation of H1975 cells with an IC50 of 0.333 μM.

Cell Viability Assay

Cell Line: AsPC-1, Panc-1 human cancer cell lines
Concentration: 0.5 μM, 4 μM, 8 μM (AsPC-1); 0.5 μM, 2 μM, 8 μM (Panc-1)
Incubation Time: 24 h, 48 h, 72 h
Result: Decreased cell viability of AsPC-1 cells in a dose- and time-dependent manner: 0.5 μM reduced viability to 62.6% (24 h), 58.3% (48 h), 44.5% (72 h); 4 μM reduced viability to 10.1% (24 h), 5.1% (48 h), 0% (72 h); 8 μM reduced viability to 3.4% (24 h), 38.6% (48 h), 2.4% (72 h).
Decreased cell viability of Panc-1 cells in a dose- and time-dependent manner: 0.5 μM reduced viability to 88.7% (24 h), 82.6% (48 h), 33.2% (72 h); 2 μM reduced viability to 60% (24 h), 9.8% (48 h), 9.5% (72 h); 8 μM reduced viability to 3.7% (24 h), 36.5% (48 h), 0.71% (72 h).

Apoptosis Analysis

Cell Line: AsPC-1 human cancer cell line
Concentration: 0, 0.25, 0.5, 1 μM
Incubation Time: 72 h
Result: Induced apoptosis in a dose-dependent manner, with the percentage of apoptotic cells increasing from 52.9% to 90.4% with higher inhibitor concentrations after 72 h treatment, compared to the control group.

Cell Cycle Analysis

Cell Line: AsPC-1 human cancer cell line
Concentration: 0, 0.25, 0.5, 1 μM
Incubation Time: 72 h
Result: Arrested cells in the G2/M phase in a dose-dependent manner: 0.25 μM increased G2/M phase cells to 5.72% and decreased G0/G1 phase cells to 63.89%; 0.5 μM increased G2/M phase cells to 15.42% and decreased G0/G1 phase cells to 57.38%; 1.0 μM increased G2/M phase cells to 27.19% and decreased G0/G1 phase cells to 39.90%.
Showed minor changes in the percentage of cells in S phase.
体内研究
(In Vivo)

EGFR T790M/FAK-IN-2 (30-60 mg/kg;口服;每日;10 天) 可剂量依赖性地抑制 BALB/c 裸鼠体内胰腺癌肿瘤的生长。

Animal Model: BALB/cJNju-Foxn1nu/Nju (nude) (female, 5-6 weeks old, 20-25 g, subcutaneous xenograft with human AsPC-1 cells)
Dosage: 30 mg/kg; 60 mg/kg
Administration: p.o.; daily; 10 days
Result: Achieved tumor growth inhibition (TGI) rate of 24.45% at 30 mg/kg dose.
Achieved tumor growth inhibition (TGI) rate of 36.6% at 60 mg/kg dose.
Exhibited dose-dependent reduction in tumor weight and volume relative to controls.

化学信息

分子量 510.00
分子式 C25H28ClN7O3
CAS No. 2143104-11-2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础